{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:17:22Z","timestamp":1773955042525,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background and objective<\/jats:title><jats:p>The relationship between antimitochondrial antibody (AMA) levels and the severity or prognosis of primary biliary cholangitis (PBC) is unclear. This study explored the clinical significance of serum IgG antimitochondrial M2 antibody (IgG-M2) levels.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>From 2008 to 2017, a retrospective analysis was conducted with PBC patients who had available quantitative values of serum IgG-M2 levels obtained with ELISA based on triple expression hybrid clones. The patients were divided into two groups based on high and low concentrations of IgG-M2. Baseline parameters, the incidence of adverse events, and prognosis were compared.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Among the 530 PBC patients, the levels of albumin, cholinesterase, hemoglobin, fibrinogen and triglycerides and the red blood cell count were significantly lower in the high-concentration group than in the low-concentration group (n = 263, 49.6%). The red cell distribution width (RDW) and levels of serum immunoglobulin (Ig) G, IgM and IgA were significantly higher in the high-concentration group than in the low-concentration group. Spearman\u2019s correlation analysis suggested that the correlation between the above baseline indicators and IgG-M2 levels was statistically significant but weak (r &lt; 0.2, P &lt; 0.05). In total, 203 patients were followed up, of whom 87 (42.9%) were in the high-concentration group. During the median follow-up period of 52 months (range: 28\u201375), 121 (59.6%) experienced hepatic decompensation, and 37 (18.2%) died or underwent liver transplantation. There was no significant difference in the incidence of complications or survival (log-rank test: P = 0.079) between the two groups. One year after ursodeoxycholic acid (UDCA) treatment, the two groups had similar responses. In addition, the levels of IgG-M2 did not fluctuate significantly during treatment.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>IgG-M2 levels were not related to the disease severity, prognosis or efficacy of UDCA. The levels of IgG-M2 did not change significantly during treatment.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0242164","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T21:10:07Z","timestamp":1605215407000},"page":"e0242164","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical significance of IgG antimitochondrial\u00a0M2 antibody levels in primary biliary cholangitis: A single center study from China"],"prefix":"10.1371","volume":"15","author":[{"given":"Lina","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-2795","authenticated-orcid":true,"given":"Qinglong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"pone.0242164.ref001","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12016-010-8234-y","article-title":"Overcoming a \"probable\" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature","volume":"42","author":"N Bizzaro","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"pone.0242164.ref002","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","article-title":"Primary biliary cholangitis: a comprehensive overview","volume":"11","author":"A Lleo","year":"2017","journal-title":"Hepatol Int"},{"key":"pone.0242164.ref003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2152\/jmi.64.7","article-title":"Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms","volume":"64","author":"K Tsuneyama","year":"2017","journal-title":"J Med Invest"},{"key":"pone.0242164.ref004","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.138.10.3525","article-title":"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis","volume":"138","author":"ME Gershwin","year":"1987","journal-title":"J Immunol"},{"key":"pone.0242164.ref005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/14737159.2016.1164038","article-title":"A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis","volume":"16","author":"PS Leung","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"pone.0242164.ref006","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2002-34506","article-title":"Immunopathogenesis of primary biliary cirrhosis","volume":"22","author":"A Nishio","year":"2002","journal-title":"Semin Liver Dis"},{"key":"pone.0242164.ref007","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10875-007-9092-0","article-title":"Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis","volume":"27","author":"S Gabeta","year":"2007","journal-title":"J Clin Immunol"},{"key":"pone.0242164.ref008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"KD Lindor","year":"2009","journal-title":"Hepatology"},{"key":"pone.0242164.ref009","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/bega.2000.0106","article-title":"The pathology of primary biliary cirrhosis and autoimmune cholangitis","volume":"14","author":"J. Ludwig","year":"2000","journal-title":"Baillieres Best Pract Res Clin Gastroenterol"},{"key":"pone.0242164.ref010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"E Christensen","year":"1980","journal-title":"Gastroenterology"},{"key":"pone.0242164.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"J Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"pone.0242164.ref012","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2169\/internalmedicine.34.496","article-title":"Immunological study of anti-M2 in antimitochondrial antibody-negative primary biliary cirrhosis","volume":"34","author":"N Kitami","year":"1995","journal-title":"Intern Med"},{"key":"pone.0242164.ref013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.510250103","article-title":"Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression","volume":"25","author":"MD Van Norstrand","year":"1997","journal-title":"Hepatology"},{"key":"pone.0242164.ref014","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2002.05620.x","article-title":"Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?","volume":"97","author":"S Joshi","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"pone.0242164.ref015","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.3748\/wjg.v11.i36.5706","article-title":"High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis","volume":"11","author":"R Flisiak","year":"2005","journal-title":"World J Gastroenterol"},{"key":"pone.0242164.ref016","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12026-016-8838-2","article-title":"Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?","volume":"65","author":"AM Alfano","year":"2017","journal-title":"Immunol Res"},{"key":"pone.0242164.ref017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s005350050380","article-title":"Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis?","volume":"34","author":"M Nakajima","year":"1999","journal-title":"J Gastroenterol"},{"key":"pone.0242164.ref018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2188\/jea.16.30","article-title":"Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid","volume":"16","author":"F Sakauchi","year":"2006","journal-title":"J Epidemiol"},{"key":"pone.0242164.ref019","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/jgh.14521","article-title":"Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China","volume":"34","author":"S Chen","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0242164.ref020","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1007\/s10620-011-1661-7","article-title":"Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients","volume":"56","author":"DT Zhao","year":"2011","journal-title":"Dig Dis Sci"},{"key":"pone.0242164.ref021","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"M Carbone","year":"2016","journal-title":"Hepatology"},{"key":"pone.0242164.ref022","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrgastro.2015.187","article-title":"Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?","volume":"12","author":"PJ Trivedi","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0242164.ref023","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary Biliary Cirrhosis","volume":"353","author":"MM Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0242164.ref024","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"EJ Carey","year":"2015","journal-title":"Lancet"},{"key":"pone.0242164.ref025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3109\/00365521.2015.1132337","article-title":"Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis","volume":"51","author":"G Juliusson","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"pone.0242164.ref026","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.gtc.2008.02.006","article-title":"Antimitochondrial antibody-negative primary biliary cirrhosis","volume":"37","author":"F Mendes","year":"2008","journal-title":"Gastroenterol Clin North Am"},{"key":"pone.0242164.ref027","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1478-3231.2007.01651.x","article-title":"Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis","volume":"28","author":"B Liu","year":"2008","journal-title":"Liver Int"},{"key":"pone.0242164.ref028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2036.2003.01381.x","article-title":"Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?","volume":"17","author":"JP Gisbert","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0242164.ref029","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis","volume":"25","author":"P Invernizzi","year":"1997","journal-title":"Hepatology"},{"key":"pone.0242164.ref030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10446670410001722113","article-title":"Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis","volume":"11","author":"GD Benson","year":"2004","journal-title":"Clin Dev Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T06:19:08Z","timestamp":1697091548000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0242164"}},"subtitle":[],"editor":[{"given":"Olivier","family":"Barbier","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0242164","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]}}}